ConductScience.org, home

Paper39736693

Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.

Sirera J and 14 others. J Exp Clin Cancer Res, 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation. Papers, record 39736693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39736693

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Disrupting USP39 deubiquitinase function impairs the survival and migration of multiple myeloma cells through ZEB1 degradation.
PubMed
Journal
J Exp Clin Cancer Res
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.26, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sirera JJessy
2Sarlak SSaharnaz
3Teisseire MManon
4Carminati AAlexandrine
5Nicolini VJVictoria J
6Savy CColine
7Brest PPatrick
8Juel TThierry
9Bontoux CChristophe
10Deckert MMarcel
11Ohanna MMickael
12Giuliano SSandy
13Dufies MMaeva
14Pages GGilles
15Luciano FFrederichttps://orcid.org/0000-0001-9253-4998

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Zinc Finger E-box-Binding Homeobox 1Major topic
Cell MovementMajor topic
Ubiquitin-Specific ProteasesMajor topic
Humans
Animals
Zebrafish
Cell Line, Tumor
Deubiquitinating Enzymes
Cell Survival
Mice

Source PubMed

Download CSV of topics

References55

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134197957USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma.Cell Signal2021https://conductscience.org/library/papers/34197957PubMed
231723771ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?Hemasphere2018https://conductscience.org/library/papers/31723771PubMed
328154181USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.J Biol Chem2017https://conductscience.org/library/papers/28154181PubMed
426513019UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression.Oncotarget2015https://conductscience.org/library/papers/26513019PubMed
537212518Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.Cancer Med2023https://conductscience.org/library/papers/37212518PubMed
633127822USP39 Serves as a Deubiquitinase to Stabilize STAT1 and Sustains Type I IFN-Induced Antiviral Immunity.J Immunol2020https://conductscience.org/library/papers/33127822PubMed
736940483USP10 Regulates ZEB1 Ubiquitination and Protein Stability to Inhibit ZEB1-Mediated Colorectal Cancer Metastasis.Mol Cancer Res2023https://conductscience.org/library/papers/36940483PubMed
824126978Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro.Oncol Rep2013https://conductscience.org/library/papers/24126978PubMed
929556295Downregulation of ubiquitin-specific peptidase 39 suppresses the proliferation and induces the apoptosis of human colorectal cancer cells.Oncol Lett2018https://conductscience.org/library/papers/29556295PubMed
1012826635A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med2003https://conductscience.org/library/papers/12826635PubMed
1127344946MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.Cancer Cell2016https://conductscience.org/library/papers/27344946PubMed
1232549302Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.Cancers (Basel)2020https://conductscience.org/library/papers/32549302PubMed
1325051369The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Oncotarget2014https://conductscience.org/library/papers/25051369PubMed
1422535658Myeloma as a model for the process of metastasis: implications for therapy.Blood2012https://conductscience.org/library/papers/22535658PubMed
1515958804Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med2005https://conductscience.org/library/papers/15958804PubMed
1620023629Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.Nature2010https://conductscience.org/library/papers/20023629PubMed
1736119839USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.Am J Cancer Res2022https://conductscience.org/library/papers/36119839PubMed
1830771428USP39 regulates DNA damage response and chemo-radiation resistance by deubiquitinating and stabilizing CHK2.Cancer Lett2019https://conductscience.org/library/papers/30771428PubMed
1935203300Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours.Cells2022https://conductscience.org/library/papers/35203300PubMed
2015650264Targeting multiple myeloma cells and their bone marrow microenvironment.Ann N Y Acad Sci2004https://conductscience.org/library/papers/15650264PubMed

See all 55 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42274330MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer.Mol Cancer Res2026https://conductscience.org/library/papers/42274330PubMed
41596492RNA-Based Therapeutic Strategies in Multiple Myeloma: From Molecular Targets to Delivery and Clinical Translation.Int J Mol Sci2026https://conductscience.org/library/papers/41596492PubMed
41208892Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance.Int J Biol Sci2025https://conductscience.org/library/papers/41208892PubMed
40734978Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease.Front Cardiovasc Med2025https://conductscience.org/library/papers/40734978PubMed
40295433Serine metabolism in tumor progression and immunotherapy.Discov Oncol2025https://conductscience.org/library/papers/40295433PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
USP3910713PubTator's text mininghttps://conductscience.org/library/genes/10713NCBI Gene
ZEB16935PubTator's text mininghttps://conductscience.org/library/genes/6935NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39736693

GET https://conductscience.org/api/papers/v1/39736693/references?page=2